Mazières, J <br/><br/>
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Feb 2016 
 - 281-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv573  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenocarcinoma of Lung<br/>Adult<br/>Afatinib<br/>Aged<br/>Aged, 80 and over<br/>Anaplastic Lymphoma Kinase<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cohort Studies<br/>Disease-Free Survival<br/>ErbB Receptors--genetics<br/>Europe<br/>Female<br/>Humans<br/>Lapatinib<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy--methods<br/>Quinazolines--therapeutic use<br/>Quinolines--therapeutic use<br/>Receptor Protein-Tyrosine Kinases--genetics<br/>Receptor, ErbB-2--genetics<br/>Retrospective Studies<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome